HUMAN WILD-TYPE P53 ADOPTS A UNIQUE CONFORMATIONAL AND PHOSPHORYLATION STATE INVIVO DURING GROWTH ARREST OF GLIOBLASTOMA CELLS

被引:0
|
作者
ULLRICH, SJ [1 ]
MERCER, WE [1 ]
APPELLA, E [1 ]
机构
[1] THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107
关键词
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The wild-type (wt) human tumor-suppressor gene product, p53, and its mutant form have been analysed in an in vivo system in which the inducible expression of wt p53 results in growth arrest in the G1 phase of the cell cycle. Two major pools of p53 are detected after wt p53 expression by their differential reactivity with the p53 monoclonal antibodies PAb 421 and 1801 as well as the mutant and wt-specific monoclonal antibodies PAb 240 and 1620; one pool contains wt and mutant p53 and is characterized as having a mutant conformation, whereas the other pool contains only wt p53 with a wt conformation. As G1 arrest is entered, the amount of wt p53 associated with the mutant pool decreases, such that by 12 h free wt and mutant p53 are the - major pools. Two-dimensional gel analysis of the p53 pools revealed that free wt p53 is phosphorylated to a greater degree than mutant p53, which correlated with the loss of the PAb 421 epitope on wt p53. In summary, the ability of wt p53 to exert an antiproliferative effect correlates with the presence of a unique conformational state of wt p53 characterized by increased phosphorylation and the loss of both the PAb 421 epitope and association with mutant p53 pool, whereas mutant p53 is unable to assume this conformational state.
引用
收藏
页码:1635 / 1643
页数:9
相关论文
共 50 条
  • [31] Telomere erosion triggers growth arrest but not cell death in human cancer cells retaining wild-type p53: implications for antitelomerase therapy
    Preto, A
    Singhrao, SK
    Haughton, MF
    Kipling, D
    Wynford-Thomas, D
    Jones, CJ
    ONCOGENE, 2004, 23 (23) : 4136 - 4145
  • [32] Telomere erosion triggers growth arrest but not cell death in human cancer cells retaining wild-type p53: implications for antitelomerase therapy
    Ana Preto
    Sim K Singhrao
    Michele F Haughton
    David Kipling
    David Wynford-Thomas
    Christopher J Jones
    Oncogene, 2004, 23 : 4136 - 4145
  • [33] Serine 312 phosphorylation is dispensable for wild-type p53 functions in vivo
    Lee, M. K.
    Tong, W. M.
    Wang, Z. Q.
    Sabapathy, K.
    CELL DEATH AND DIFFERENTIATION, 2011, 18 (02): : 214 - 221
  • [34] Serine 312 phosphorylation is dispensable for wild-type p53 functions in vivo
    M K Lee
    W M Tong
    Z Q Wang
    K Sabapathy
    Cell Death & Differentiation, 2011, 18 : 214 - 221
  • [35] Wild-type p53 reduces radiation hypermutability in p53-mutated human lymphoblast cells
    Zhang, Qinming
    Liu, Yunfeng
    Zhou, Juntling
    Chen, Weihong
    Zhang, Ying
    Liber, Howard L.
    MUTAGENESIS, 2007, 22 (05) : 329 - 334
  • [36] Radiosensitivity of human breast cancer cells transduced with wild-type p53 gene is influenced by the p53 status of parental cells
    Maeda, T
    Matsubara, H
    Koide, Y
    Sugaya, M
    Miyazawa, Y
    Tasaki, K
    Isono, K
    Ochiai, T
    Sakiyama, S
    Tagawa, M
    ANTICANCER RESEARCH, 2000, 20 (2A) : 869 - 874
  • [37] NEGATIVE GROWTH-REGULATION IN A GLIOBLASTOMA TUMOR-CELL LINE THAT CONDITIONALLY EXPRESSES HUMAN WILD-TYPE P53
    MERCER, WE
    SHIELDS, MT
    AMIN, M
    SAUVE, GJ
    APPELLA, E
    ROMANO, JW
    ULLRICH, SJ
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (16) : 6166 - 6170
  • [38] Mitochondrially targeted wild-type p53 suppresses growth of mutant p53 lymphomas in vivo
    Palacios, G.
    Moll, U. M.
    ONCOGENE, 2006, 25 (45) : 6133 - 6139
  • [39] Mitochondrially targeted wild-type p53 suppresses growth of mutant p53 lymphomas in vivo
    G Palacios
    U M Moll
    Oncogene, 2006, 25 : 6133 - 6139
  • [40] EXPRESSION OF WILD-TYPE P53 IN HUMAN A673 CELLS SUPPRESSES TUMORIGENICITY BUT NOT GROWTH-RATE
    CHEN, YM
    CHEN, PL
    ARNAIZ, N
    GOODRICH, D
    LEE, WH
    ONCOGENE, 1991, 6 (10) : 1799 - 1805